Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

作者：Xiangrui Meng, Tao Wu, Yonggui Hong, Qingxia Fan, Zhonghai Ren, Yanzhen Guo, Xiuli Yang, Pei Shi, Jiamei Yang, Xianzhe Yin, Zhiquan Luo, Jin Xia, Yue Zhou, Mengli Xu, Enjie Liu, Guozhong Jiang, Shenglei Li, Feng Zhao, Chi Ma, Chuanxiang Ma, Zhiguo Hou, Jing Li, Junsheng Wang, Feng Wang · 发表于：˜The œLancet. Gastroenterology & hepatology · 年份：2022 · DOI：10.1016/s2468-1253(21)00378-2 · 被引用次数：88 · 研究领域：Esophageal Cancer Research and Treatment、Cancer Immunotherapy and Biomarkers、Colorectal and Anal Carcinomas